The research peptide market has no central quality authority. Unlike pharmaceutical supply chains with FDA oversight, research compound suppliers self-report purity figures that buyers have no practical way to verify. A supplier claims 99% HPLC purity on their product page. Is that number real? Was it tested this batch, or three years ago? Most researchers never find out.
We wanted to find out. Over a 60-day period, we placed standard orders from the eight most frequently recommended US-based research peptide suppliers. We ordered the same five core compounds from each supplier where available: BPC-157, Semaglutide, NAD+, CJC-1295/Ipamorelin, and TB-500. Every sample was sent to an independent analytical laboratory for HPLC purity analysis under blinded conditions. The lab did not know which sample came from which supplier.
The results varied more than we expected.
Of the 38 samples tested, 29 (76%) met or exceeded their label purity claim. Nine samples (24%) tested below their stated purity, with the largest gap being a Semaglutide sample labeled at 99% that tested at 91.3%. Two suppliers consistently exceeded 98% across all compounds tested. One supplier had no sample above 95%.